# Tirzepatide and Blood Pressure: What the Research Shows **By TelosRX Editorial Team** · 2026-10-07 **Tirzepatide and blood pressure are closely linked in clinical trials. In SURMOUNT-1, tirzepatide lowered systolic pressure by roughly 7 to 11 mm Hg versus placebo, mostly through weight loss. [TelosRX](https://telosrx.com) breaks down what the studies found.** Most people start a GLP-1 for the scale. The blood pressure readings are often the surprise. This review walks through what published tirzepatide and blood pressure research actually measured. It covers the numbers, the caveats, and what it means if you already take blood pressure medication. ## Why Blood Pressure Matters on a Weight-Loss Medication Excess weight raises blood pressure in several ways. It increases blood volume, stiffens arteries, and strains the kidneys. Tirzepatide is a dual agonist. That means it activates two gut-hormone receptors, GIP and GLP-1. Together they slow digestion, curb appetite, and improve how your body handles glucose. So researchers asked a fair question. If tirzepatide drives large weight loss, does blood pressure follow? Four findings stand out. ## Finding 1: SURMOUNT-1 Showed Lower Office Blood Pressure SURMOUNT-1 was the main 72-week obesity trial for tirzepatide. It enrolled 2,539 adults with obesity or overweight who did not have diabetes. - **Baseline:** average systolic pressure was about 123 mm Hg, already near normal. - **Weight:** average loss was 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses, versus 3.1% on placebo. - **Blood pressure:** the authors reported greater improvements in both systolic and diastolic pressure than placebo. Those results were published in the [New England Journal of Medicine in 2022](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). Office readings are a snapshot, though. That led to a closer look. ## Finding 2: 24-Hour Monitoring Confirmed the Drop A planned substudy used ambulatory blood pressure monitoring (a cuff worn for a full day and night). It captured readings every 30 minutes awake and hourly asleep. Of 600 enrolled participants, 494 had valid data at baseline and week 36. Compared with placebo, 24-hour systolic pressure fell by: - **7.4 mm Hg** on 5 mg - **10.6 mm Hg** on 10 mg - **8.0 mm Hg** on 15 mg The drop showed up during the day and at night. That matters, because nighttime pressure is a strong predictor of cardiovascular risk. Heart rate rose by about 2 to 5 beats per minute, which is typical for this drug class. The [2024 substudy in _Hypertension_](https://pubmed.ncbi.nlm.nih.gov/38314555/) estimated that about 70% of the systolic change was explained by weight loss. **Curious whether tirzepatide fits your health picture?** Review how the [TelosRX tirzepatide program](https://www.telosrx.com/pages/tirzepatide) works. Every prescription is subject to medical approval by a licensed provider after an asynchronous review of your intake. ## Finding 3: The 72-Week Picture Held Up A 2024 stratified analysis in the journal _Heart_ looked at all SURMOUNT-1 participants across the full 72 weeks. - **Systolic:** −8.1 mm Hg with pooled tirzepatide versus −1.3 mm Hg with placebo. - **Diastolic:** −5.3 mm Hg versus −1.0 mm Hg. - **Normal readings at week 72:** 58.0% of tirzepatide participants versus 35.2% on placebo. - **Weight's role:** weight loss explained an estimated 67.6% of the systolic drop and 71.0% of the diastolic drop. Pressure fell fastest over the first 24 weeks, then leveled off. You can read the full [stratified SURMOUNT-1 analysis on PubMed Central](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420724/). ## Finding 4: Low-Pressure Side Effects Were Uncommon but Real Lower blood pressure is not always good news. If it drops too far, you can feel dizzy or faint. The same 72-week analysis tracked these events: - **Dizziness:** 4.6% on tirzepatide versus 2.3% on placebo. - **Hypotension (low blood pressure):** 1.0% versus 0%. - **Orthostatic hypotension (a drop when standing):** 0.6% versus 0%. Serious events were rare, at 0.2% of tirzepatide participants. Still, these numbers explain why providers watch blood pressure medications closely during weight loss. ## Tirzepatide and Blood Pressure: The Research at a Glance Study Design Key blood pressure finding Main caveat SURMOUNT-1 (NEJM, 2022) 72-week randomized trial, 2,539 adults Greater systolic and diastolic improvement than placebo Blood pressure was a secondary measure ABPM substudy (_Hypertension_, 2024) 24-hour monitoring, 494 analyzed Systolic −7.4 to −10.6 mm Hg vs placebo at 36 weeks Only two measurement points Stratified analysis (_Heart_, 2024) Post hoc, full trial population Systolic −6.8 mm Hg net vs placebo at 72 weeks Medication changes not tracked well Safety data (same analysis) Adverse event review Hypotension in 1.0% vs 0% on placebo Short-term follow-up only ## What the Research Doesn't Tell Us These are strong trials. They still leave real gaps. - **No hypertension indication.** Brand-name tirzepatide (Mounjaro, Zepbound) is FDA-approved, but neither label lists high blood pressure as a use. - **Manufacturer funding.** The trials and analyses were funded by the drug's maker. - **Diet and salt weren't measured.** Changes in sodium intake may explain part of the effect. - **Stopping is a question mark.** Whether pressure rebounds after discontinuation is not yet well studied. - **Compounded versions weren't studied.** Compounded tirzepatide is not FDA-approved, and these trials used the brand product. Read our companion review on [tirzepatide and cardiovascular research](https://www.telosrx.com/blogs/glp1/tirzepatide-cardiovascular-research-evidence) for the heart-outcome side of the story. ## If You Already Take Blood Pressure Medication This is where the research becomes practical. As weight comes off, a dose that once fit may become too strong. 1. **Tell your prescriber every medication you take.** Include diuretics, ACE inhibitors, and beta blockers. 2. **Track readings at home.** A simple upper-arm cuff and a log help your provider spot trends. 3. **Stay hydrated.** Nausea or vomiting can cause dehydration, which can lower pressure further. 4. **Stand up slowly.** If you feel lightheaded, report it rather than pushing through. 5. **Never adjust doses yourself.** Changes to any blood pressure medicine belong with the provider who prescribes it. Our [tirzepatide side effects guide](https://www.telosrx.com/blogs/glp1/tirzepatide-side-effects-guide) covers dehydration and GI effects in more detail. You can also compare formats on our [GLP-1 options page](https://www.telosrx.com/pages/glp-1-options). ## Frequently Asked Questions ### Does tirzepatide lower blood pressure? In the SURMOUNT-1 trial, tirzepatide lowered blood pressure compared with placebo. A 24-hour monitoring substudy found systolic drops of 7.4 to 10.6 mm Hg at 36 weeks. Most of the effect appears to come from weight loss. Tirzepatide is not FDA-approved as a blood pressure medication, so any changes to your current medicines should be guided by your provider. ### How long does it take for tirzepatide to lower blood pressure? In a 72-week analysis of SURMOUNT-1, blood pressure fell fastest over the first 24 weeks, then leveled off. Individual timelines vary with dose, starting pressure, and how quickly weight comes off. Home readings shared with your provider give the clearest picture of your own trend. ### Can tirzepatide cause low blood pressure? It can, though it was uncommon in trials. Hypotension was reported in 1.0% of tirzepatide participants versus 0% on placebo, and dizziness in 4.6% versus 2.3%. The risk may be higher if you take blood pressure medications or become dehydrated from nausea or vomiting. Report lightheadedness or fainting to your provider promptly. ### Should I stop my blood pressure medication on tirzepatide? No, not on your own. As weight drops, some people need lower doses of blood pressure medication, but only the prescriber of that medication should make changes. Keep a home blood pressure log and share it, so dose adjustments are based on real readings rather than guesswork. ### Is the blood pressure drop from tirzepatide or from weight loss? Mostly weight loss, according to the research. A 72-week stratified analysis estimated weight loss explained 67.6% of the systolic drop and 71.0% of the diastolic drop. The remaining share may reflect other drug effects, diet changes, or lower salt intake, which the trial did not measure. ### Does compounded tirzepatide have the same blood pressure effect? That hasn't been studied. The SURMOUNT-1 trials used brand-name tirzepatide. Compounded tirzepatide contains the same active ingredient but is not FDA-approved and was not part of these trials. Your provider can explain what the research does and doesn't cover before you decide. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Start your private evaluation at [TelosRX](https://telosrx.com). **Tags:** blood pressure, GLP-1 research, hypertension, research review, SURMOUNT-1, tirzepatide --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/tirzepatide-and-blood-pressure-research)